Prioritizing Future Research on Off‐Label Prescribing: Results of a Quantitative Evaluation
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Study Objective. To develop a prioritized list of individual drugs for which future research regarding off‐label uses is warranted. Design. Retrospective, cross‐sectional study. Data Sources. Commercial database that provides ongoing estimates of drug prescribing practices of office‐based physicians in the United States and an Internet database of comprehensive evidence‐based drug information. Measurements and Main Results. The base analyses incorporated three key factors based on the theory of value of information: volume of off‐label use with inadequate evidence, drug safety, and cost and market considerations. Nationally representative prescribing data were used to estimate the number of off‐label drug uses by indication from January 1, 2005‐June 30, 2007, in the United States, and these indications were then categorized according to the adequacy of scientific support. Black‐box warnings and safety alerts, drug cost, date of market entry, and marketing expenditures were also incorporated into the final model to produce a priority score. Sensitivity analyses were conducted by varying key model parameters. Our findings identified a high volume of off‐label prescribing in the absence of good evidence for a substantial number of drugs, particularly antidepressants, antipsychotics, and anxiolytic‐sedatives. Drugs that consistently ranked high in both our base model and sensitivity analyses were quetiapine, warfarin, escitalopram, risperidone, montelukast, bupropion, sertraline, venlafaxine, celecoxib, lisinopril, duloxetine, trazodone, olanzapine, and epoetin alfa. Conclusion. Future research into off‐label drug use should focus on drugs used frequently with inadequate supporting evidence, particularly if further concerns are raised by known safety issues, high drug cost, recent market entry, and extensive marketing. Our quantitative analysis identified particular concerns with the off‐label use of antipsychotic and antidepressant drugs. Targeted research and policy activities on our list of prioritized drugs have high potential value.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937 · cited 1×
“Even as an adjunct to other therapies in depressive episodes, antidepressants do not appear to be effective for bipoplar disorder.(24) Hence, we view these drugs as valuable focal points for future research.”
BackgroundOff-label prescribing among office-based physicians
Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1021 · Cited by 711 · cited 1×
“The third study examined the frequency and uses of off-label prescribing for common drugs as a function of the strength of scientific support for those uses.(9) Of the estimated 21% of drug uses that were off-label, 73% did not have good scientific support.”
BackgroundDepression treatment during outpatient visits by U.S. children and adolescents
Ma, J., Lee, K.-V., & Stafford, R. S. (2005) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2005.07.012 · Cited by 68
Self-citation
Cited by
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Mojtabai, R., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.175 · Cited by 479
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
Eguale, T., Buckeridge, D. L., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.6058 · Cited by 262
Wong, J., Motulsky, A., Abrahamowicz, M., Eguale, T., Buckeridge, D. L., & Tamblyn, R. (2017) · BMJ · doi:10.1136/bmj.j603 · Cited by 221
Americans' Attitudes Toward Psychiatric Medications: 1998–2006
Mojtabai, R. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.8.1015 · Cited by 57
Adverse reactions to duloxetine in depression
Bitter, I., Filipovits, D., & Czobor, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.582037 · Cited by 38
“In a retrospective analysis of off-label prescribing of antidepressant drugs including duloxetine, bipolar disorder was the most common condition inciting off-label use [39].”
Background
Metadata
- Authors
- Walton, S. M., Schumock, G. T., Lee, K., Alexander, G. C., Meltzer, D., & Stafford, R. S.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2008-12
- Volume
- 28
- Issue
- 12
- Pages
- 1443-1452
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2171049004
- Cited by
- 96
- References
- 3
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.